These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30468397)

  • 1. Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital.
    Santoleri F; Romagnoli A; Costantini A
    Future Oncol; 2019 Jan; 15(1):45-51. PubMed ID: 30468397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
    Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
    BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
    Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
    Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
    Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
    BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
    Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
    BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
    Ingrasciotta Y; Sultana J; Formica D; Ientile V; Aiello A; Chinellato A; Tari DU; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Rossi M; Santoro D; Trifirò G;
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):65-77. PubMed ID: 33067914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.